Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.

A legfontosabb adatok

Ki végzi
Centre Hospitalier Universitaire de Nice
Hol
Franciaország5 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
56 fő, tervezett
Kezdés
2026. okt. 1.
Várható befejezés
2028. nov. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Upadacitinib
  • Placebo
A regiszteradat frissítve
2026. október 1.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with biopsy-proven erosive mucosal lichen planus or active lichen planopilaris. It tests upadacitinib 30 mg against placebo.

Életkor
18 to under 65 years
Nem
Men and women
A betegség stádiuma
Mucosal lichen planus or active lichen planopilaris, confirmed by biopsy. Disease must be moderate or severe (IGA score of ≥ 3) and need treatment taken by mouth or injection.
Korábbi kezelés
The disease did not respond well enough to strong (high to ultrahigh potency) steroid creams or ointments.

A részvétel fő kizáró okai

  • Lichen planus that may be caused by a drug or linked to a cancer
  • Burnt-out scarring hair loss, or frontal fibrosing alopecia without active lichen planopilaris patches
  • HIV, active tuberculosis, active hepatitis B or C, or serious repeated shingles or herpes infections
  • Stroke, heart attack or blood clot in the past 6 months, organ transplant needing ongoing immune suppression, or past cancer (with some exceptions)
  • Pregnant, breastfeeding or planning pregnancy during the study and for 30 days after

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Written informed consent must be obtained before any assessment is performed
  • Female and male patients ≥ 18 years and < 65 years old at Baseline Visit
  • Subjects must have biopsy-confirmed forms of mucosal lichen planus (MLP) or active lichen planopilaris (LPP) eligible for systemic therapy based on the following criteria:; Rated IGA of ≥ 3 (moderate or severe) AND; Inadequate response to topical corticosteroids of high - ultrahigh potency in the opinion of the investigator
  • A negative serum pregnancy test for all female subjects considered to be of childbearing potential at the Screening Visit and a negative urine pregnancy test at baseline prior to the first dose of study drug

Ki nem vehet részt

  • Clinical history suspicious for lichenoid drug eruption
  • History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months prior to Baseline
  • Meeting any of the following conditions at Baseline:; Three or more prior episodes of herpes zoster, or one or more episodes of disseminated herpes zoster; One or more prior episodes of disseminated herpes simplex (including eczema herpeticum); Human immunodeficiency virus (HIV) infection, defined as confirmed positive anti-HIV antibody (HIV Ab) test or a positive HIV Ab/Ag test; Active tuberculosis (TB) or meet TB exclusionary parameters; Active infection(s) requiring treatment with intravenous anti-infectives within 30 days, or oral/intramuscular anti-infectives within 14 days prior to the Baseline Visit; Chronic recurring infection and/or active viral infection that, based on the investigator's clinical assessment, makes the subject an unsuitable candidate for the study; Hepatitis B virus (HBV) and hepatitis C virus (HCV) screening values that meet the following criteria at the most recent testing prior to the first dose of study treatment:; HBV: hepatitis B surface antigen (HBs Ag) positive (+) test or detectable HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for subjects who are hepatitis B core antibody (HBc Ab) positive (+); HCV: detectable HCV ribonucleic acid (RNA) in any subject with anti-HCV antibody (HCV Ab)
  • Female subjects of childbearing potential who are not able and/or willing to practice at least 1 protocol-specified method of birth control that is highly effective from Study Day 1 through at least 30 days after the last dose of study drug (local practices may require an additional method of contraception). Female subjects of non-childbearing potential do not need to use birth control
  • Female subjects who are pregnant, breastfeeding, or considering becoming pregnant or donating eggs during the study and for 30 days after the last dose of study drug
  • Subjects who have been treated with any investigational drug of chemical or biologic nature within 30 days or five half-lives (whichever is longer) prior to the first dose of study drug or who are currently enrolled in another interventional clinical study
  • Subjects with systemic use of known strong cytochrome P450 3A (CYP3A) inhibitors or strong CYP3A inducers 30 days prior to study treatment administration (refer to the Table in section 5. for examples of commonly used strong CYP3A inhibitors and inducers)
  • Subjects who have received any live vaccine with replicating potential within 30 days prior to the first dose of study drug, or have expected need of vaccination with any live vaccine with replicating potential during study participation including at least 30 days after the last dose of study drug. Live vaccines that are incapable of replicating are permitted
  • At Baseline any of the following medical diseases or disorders:; Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting, aorto-coronary bypass surgery, or venous thromboembolism; History of an organ transplant which requires continued immunosuppression; History of an allergic reaction or significant sensitivity to constituents of the study drug and/or other products in the same class; History of gastrointestinal (GI) perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment; Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery (including sleeve gastrectomy); subjects with a history of gastric banding/segmentation are not excluded; History of malignancy except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix
  • History of or current clinically significant medical conditions or any other reason that in the opinion of the Investigator would interfere with the subject's participation in this study, would place the subject at risk by participating in the study or would make the subject an unsuitable candidate to receive study drug, also with regard to the European Commission Decision as of 10 March 2023 on measures to minimize risk of serious side effects with Janus kinase inhibitors (EMA/142279/2023)
  • Females of child-bearing potential who meet the following criteria for pregnancy testing:; Subjects with a positive serum pregnancy test at the Screening Visit or a positive urine pregnancy test at Baseline prior to the first dose of study treatment (local practices may require serum pregnancy testing at Baseline); Subjects with a borderline serum pregnancy test at Screening must have absence of clinical suspicion of pregnancy or other pathological causes of borderline results and a serum pregnancy test ≥ 3 days later to document continued lack of a positive result (unless inclusion of subjects with a borderline pregnancy test may be prohibited by local requirements); Subjects with a urine pregnancy test at Baseline that is borderline or ambiguous must have a serum pregnancy test performed. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive
  • Screening laboratory values that meet the following criteria at the most recent testing prior to the first dose of study drug:; Serum aspartate transaminase (AST) > 2 × ULN; Serum alanine transaminase (ALT) > 2 × ULN; Estimated glomerular filtration rate (GFR) by simplified 4-variable MDRD formula < 30 mL/min/1.73 m2; Total white blood cell (WBC) count < 2,500/µL; Absolute neutrophil count (ANC) < 1,200/µL; Platelet count < 100,000/µL; Absolute lymphocyte count < 750/µL; Hemoglobin < 9 g/dL
  • Clinical picture or history suspicious of paraneoplastic mucosal lichen planus
  • Mucosal lichen planus of the oral cavity or gastrointestinal involvement requiring the patient to use parenteral nutrition or feeding tube
  • Clinical picture of burnt-out cicatricial alopecia (alopecia of Brocq)
  • Patients diagnosed with frontal fibrosing alopecia (FFA) without active patches of LPP
  • Withdrawal of the informed consent

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Lichen planus (LP) is a common immune-mediated skin disease with a prevalence of 1-2% in the general population. It can present with a broad spectrum of clinical manifestations affecting primarily the skin (cutaneous LP [CLP]), the mucosae (mucosal LP [MLP]), hair follicles (lichen planopilaris [LPP]), or nails (nail lichen planus (NLP). The often treatment-refractory nature of the disease, the pronounced itch of CLP lesions, the pain of erosive MLP lesions, and the visible impact of NLP or LPP induced hair loss are well reflected by the poor quality of life (QoL) of patients with LP. There is no treatment for LP approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA). The pathogenesis of LP is now better understood. LP lesions are infiltrated with T cells, including CD8+ and CD4+ populations. CD8+ T cells, mainly located around the basal layer of the epidermis, can trigger apoptosis of epidermal keratinocytes. Recent data underline the role of the Th1 response in LP suggesting that oral inhibitors of Janus Kinase 1 (JAK1) could be of interest. This is supported by isolated cases and open series of successful treatment of CLP, erosive MLP and LPP by several topical and oral JAK inhibitors (JAKi), including upadacitinib. However, the results are variable depending on patient characteristics, type of JAKi and doses used. Upadacitinib is a selective JAK1 inhibitor and provides a good safety profile. We hypothesize that it could be an effective option for LPP and erosive MLP, the most severe and disabling forms of LP.

A teljes eredeti leírásKevesebb

This is a multicenter, randomized, double-blind, placebo-controlled, parallel- group trial assessing the efficacy and safety of upadacitinib 30 mg in patients with biopsy-proven LPP or erosive MLP.

A vizsgálat 2 csoportja

  • DrugA vizsgált kezelés

    28 patients for each condition (56 total) to upadacitinib 30mg QD for 16 weeks.

    Kezelés: Upadacitinib

  • PlaceboPlacebo, összehasonlításként

    28 patients to placebo n30mg QD for 16 weeks.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study (UPA_LP).
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Illeszkedési kérdések
Forrás: NCT07492251: ki vehet részt
A regiszteradat frissítve
2026. október 1.